Abstract
Many patients with advanced Parkinson's disease (PD) experience motor complications,
which negatively impact quality of life, despite optimized oral therapy. It is important
for patients to have a treatment option that may provide rapid relief from “off” episodes.
In three pivotal, randomized, placebo-controlled trials, subcutaneous apomorphine
was effective in acutely treating “off” episodes, significantly improving Unified
Parkinson Disease Rating Scale motor scores and reducing the number of “off” hours
per day, with a significantly shorter time to patient-declared onset of relief than
placebo. Thus, clinical trial data support the efficacy of intermittent subcutaneous
apomorphine as a rapid acute treatment for “off” episodes in advanced PD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Parkinsonism & Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of parkinsonism.in: Parkinson's disease: diagnosis and clinical management. Demos, New York2002: 31-40
- Pharmacotherapy for advanced Parkinson's disease.Pharmacotherapy. 2000; 20: 8S-16S
- Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.Mov Disord. 2001; 16: 448-458
- Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.Mov Disord. 2005; 20: 726-733
- Implications of motor fluctuations in Parkinson's disease patients on chronic therapy (IMPACT): results from an observational registry.Mov Disord. 2005; 20: S146
- Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: relationship between Hoehn & Yahr stage and patient- and disease-related characteristics.Mov Disord. 2006; 21: S95
- Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: comparison of patient- and physician-reported data.Mov Disord. 2006; 21: S92
- Impact of the motor complications of Parkinson's disease on the quality of life.Mov Disord. 2005; 20: 224-230
- Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: quality of life (QOL) data.Mov Disord. 2006; 21: S151
- Rapid treatment of “wearing off” in Parkinson's disease.Neurology. 2004; 62: S27-S31
- Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.Mov Disord. 1994; 9: 463-465
- Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.Neurology. 1996; 47: 1493-1495
Data on file. Vernalis Pharmaceuticals Inc. Study APO301.
- Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.J Neurol Neurosurg Psychiatry. 1993; 56: 101-103
- A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.Arch Neurol. 2001; 58: 1385-1392
- Efficacy of sublingual apomorphine in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1990; 53: 1105
- Subcutaneous apomorphine in the treatment of Parkinson's disease.J Neurol Neurosurg Psychiatry. 1990; 53: 96-101
- Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.J Neurol Neurosurg Psychiatry. 1998; 65: 709-716
- Subcutaneous apomorphine in Parkinson's disease.Lancet. 1988; 1: 943
- Subcutaneous apomorphine in parkinsonian on–off oscillations.Lancet. 1988; 1: 403-406
- A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson's disease.Clin Neurol Neurosurg. 1993; 95: 231-235
Apokyn (apomorphine hydrochloride injection) prescribing information. Morristonw, NJ: Vernalis Pharmaceuticals Inc.; 2004.
- APO303 investigators. A double-blind placebo-controlled study of the efficacy of a single dose of subcutaneous apomorphine in Parkinson's disease.Neurology. 2004; 62: A329
- Management of motor complications in Parkinson's disease.Neurology. 2004; 62: S3-S7
- Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.Neurology. 2004; 62: S12-S17
- On–off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.Brain. 1984; 107: 487-506
- Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on–off phenomenon.J Neurol Neurosurg Psychiatry. 1996; 60: 634-637
- The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.Clin Neuropharmacol. 1992; 15: 501-504
- Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.Clin Neuropharmacol. 1997; 20: 165-167
- The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon “off” periods in Parkinson's disease.Clin Neuropharmacol. 1991; 14: 241-244
- Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.Ann Neurol. 1996; 39: 400-404
- Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.Parkinsonism Relat Disord. 2007; 13: 93-100
- Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.J Neurol Neurosurg Psychiatry. 1995; 58: 681-687
- A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.Mov Disord. 1998; 13: 782-787
- Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.Clin Neuropharmacol. 1991; 14: 432-437
- Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.Clin Neuropharmacol. 1991; 14: 556-561
- Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease.Clin Neuropharmacol. 1999; 22: 1-4
- Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.Drugs Aging. 1997; 10: 332-340
- Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.Mov Disord. 1993; 8: 165-170
- Practical considerations in the use of apomorphine injectable.Neurology. 2004; 62: S32-S36
Article info
Publication history
Accepted:
July 18,
2007
Received in revised form:
July 13,
2007
Received:
February 7,
2007
Identification
Copyright
© 2007 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
